at CNBC.com (Mon, 8:34AM)
More on Allergan (AGN) Q3: net profit almost flat at $249.4M. Specialty pharmaceuticals sales +8.1%, medical devices -4%. Exploring options for obesity intervention business, including selling it. Guidance: Q4 EPS of $1.18-$1.20 vs consensus of $1.20, revenue of $1.47B-$1.545B vs $1.51B; FY EPS of $4.17-$4.19 vs $4.17 and revenue of $5.695B-$5.77B and $5.82B. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Nasdaq.com (Jan 21, 2015)
at Zacks.com (Jan 16, 2015)
at Zacks.com (Jan 15, 2015)
at Zacks.com (Jan 14, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs